British drugmaker GlaxoSmithKline on Tuesday agreed to buy Aiolos Bio for up to $1.4 billion, with focus on an asthma medication still at the testing stage.
This article was originally published on this website.
GSK buys asthma drug developer for up to $1.4 bn
